Abstract
There have already been some therapies for cancer, but further research is still in urgent need to effectively treat prostate cancer. Chimeric antigen receptor T (CAR-T) cells therapy is a popular new therapy to treat tumor, although it is mostly in the clinical research stage except for a few specific applications. Prostate cancer is a type of malignancy tumor in man occurring frequently. It has the second highest incidence in man and the fifth highest fatality rate worldwide. At present, the main treatment for prostate cancer includes reduce the androgen concentration of patients through drugs, operation to remove prostate tumor, pelvic radio therapy and chemotherapy. On how CAR-T works to treat prostate cancer, more study is currently being done. This review introduces the structure and the feasibility of CAR-T as a means of treating prostate cancer due to the research of three antigens which have prostate specific (prostate specific membrane antigen, prostate stem cell antigen and epithelial cell adhesion molecule) and discusses their application in prostate cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Highlights in Science, Engineering and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
